LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

Search

Design Therapeutics Inc

Gesloten

5.78 -1.2

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

5.61

Max

5.99

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.4M

-19M

Winstmarge

-2,321.599

Werknemers

57

EBITDA

-1.3M

-22M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-14.68% downside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

109M

334M

Vorige openingsprijs

6.98

Vorige sluitingsprijs

5.78

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Design Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 sep 2025, 17:03 UTC

Belangrijke Marktbewegers

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 sep 2025, 16:49 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

GD Culture Shares Drop After Deal for Pallas Capital

16 sep 2025, 16:11 UTC

Belangrijke Marktbewegers

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 sep 2025, 23:40 UTC

Marktinformatie

Nikkei May Decline as Yen Strengthens -- Market Talk

16 sep 2025, 23:34 UTC

Marktinformatie

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 sep 2025, 23:20 UTC

Marktinformatie

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 sep 2025, 21:10 UTC

Acquisities, Fusies, Overnames

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 sep 2025, 20:51 UTC

Marktinformatie

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 sep 2025, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

16 sep 2025, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

16 sep 2025, 20:25 UTC

Winsten

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 sep 2025, 20:24 UTC

Winsten

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 sep 2025, 19:19 UTC

Marktinformatie

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 sep 2025, 18:52 UTC

Marktinformatie

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 sep 2025, 18:44 UTC

Marktinformatie

Global Equities Roundup: Market Talk

16 sep 2025, 18:44 UTC

Marktinformatie

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 sep 2025, 18:40 UTC

Acquisities, Fusies, Overnames

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 sep 2025, 18:38 UTC

Marktinformatie

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 sep 2025, 18:19 UTC

Marktinformatie

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 sep 2025, 18:01 UTC

Marktinformatie

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 sep 2025, 17:34 UTC

Marktinformatie

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 sep 2025, 16:53 UTC

Winsten

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 sep 2025, 16:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

16 sep 2025, 16:15 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Commodities Roundup: Market Talk

16 sep 2025, 16:09 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Energy Roundup: Market Talk

16 sep 2025, 16:09 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 sep 2025, 15:35 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

16 sep 2025, 15:35 UTC

Marktinformatie

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 sep 2025, 15:22 UTC

Marktinformatie

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 sep 2025, 15:21 UTC

Marktinformatie

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Peer Vergelijking

Prijswijziging

Design Therapeutics Inc Prognose

Koersdoel

By TipRanks

-14.68% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 5 USD  -14.68%

Hoogste 5 USD

Laagste 5 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Design Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

2 ratings

0

Buy

2

Hold

0

Sell

Technische score

By Trading Central

3.26 / 3.63Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
help-icon Live chat